<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Propentofylline (HWA 285, 3-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1-(5-oxo-<z:chebi fb="0" ids="24593">hexyl</z:chebi>)-7-propylxanthine) is an <z:chebi fb="3" ids="16335">adenosine</z:chebi> uptake and <z:chebi fb="0" ids="50218">phosphodiesterase inhibitor</z:chebi> that has been shown to be neuroprotective in both global and permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> animal models </plain></SENT>
<SENT sid="1" pm="."><plain>However, to date, the efficacy of propentofylline has never been examined in an animal model of temporary focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or the 'therapeutic window' systematically examined in a focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> model </plain></SENT>
<SENT sid="2" pm="."><plain>The present experiments were designed to investigate these </plain></SENT>
<SENT sid="3" pm="."><plain>Temporary (3 h) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> was accomplished by the monofilament method </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volumes were determined at 24 h from 2,3,5-triphenyltetrazolieum <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) stained coronal slices </plain></SENT>
<SENT sid="5" pm="."><plain>Animals were dosed with vehicle or propentofylline at 3 mg/kg bolus and/or a 6 mg/kg per h infusion (24 h infusion) at 30 min, 1 h or 3 h post <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Physiological monitoring on a subset of animals indicated no changes in mean arterial pressure, blood gases, blood pH, and <z:chebi fb="105" ids="17234">glucose</z:chebi> levels with either <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or drug treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Propentofylline treatment resulted in a statistically significant decrease in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume when an infusion dose of 6 mg/kg per h was initiated at 30 min or when a bolus of 3 mg/kg plus an infusion dose was initiated at 1 h but not 3 h post <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, propentofylline is neuroprotective in a model of temporary focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>This suggests that combination therapy with propentofylline might lead to clinical improvement beyond that which would occur with thrombolytics alone </plain></SENT>
<SENT sid="10" pm="."><plain>The apparent short window of opportunity for effective dosing is consistent with the proposed mechanism of action for propentofylline </plain></SENT>
</text></document>